Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Poxel : to Host Conference Call for First Half 2020 Financial Results on September 15, 2020

share with twitter share with LinkedIn share with facebook
09/03/2020 | 12:46pm EDT

POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that it will report and present its financial results for the first half 2020 on Tuesday, September 15, 2020.

The management team will host a conference call on September 15, 2020 in English at 1:30 pm EDT (New York time) / 7:30 pm CEST (Paris time) to present the financial results and provide a corporate update.

To access the conference call, please use the dial-in numbers below according to your location.

US: +1 64 67 22 49 16
UK: +44 20 71 94 37 59
FR: +33 1 72 72 74 03
Access code: 97417835#

A slide presentation to accompany the conference call will be available in the Investors / Company Info / Corporate Presentations section of the Poxel website: https://www.poxelpharma.com/en_us/investors/company-information/corporate-presentations

Following the live call, a replay will be available for 90 days. To access the replay, please use one of the following numbers.

US: +1 (646) 722 4969
UK: +44 20 33 64 51 47
FR: +33 (0)1 70 71 01 60
Access code: 418947860#

About Poxel SA

Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel’s first-in-class lead product, targets mitochondrial dysfunction. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. A Japanese new drug application (J-NDA) is under review by the Pharmaceuticals and Medical Devices Agency (PMDA) to request approval for the manufacturing and marketing of Imeglimin for the treatment of type 2 diabetes. Poxel also established a partnership with Roivant Sciences for Imeglimin’s development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a MPC inhibitor, is in a single Phase 2 trial for the treatment of NASH. Poxel also has additional earlier-stage programs from its AMPK activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: www.poxelpharma.com.

In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March 12, 2020, the Company is regularly reviewing the impact of the outbreak on its business.

As of the date of this press release, and based on publicly available information, the Company has not identified the occurrence of any material negative effect on its business due to the COVID-19 pandemic, other than the delay in the initiation of the Phase 2 study enrollment for its drug candidate PXL065, which the Company initially planned during the second quarter of 2020 and was initiated on September 2, 2020. However, the Company anticipates that the COVID-19 pandemic could have further material negative impact on its business operations. The worldwide impact of COVID-19 may notably affect the Company’s internal organization and efficiency, particularly in countries where it operates and where confinement measures are implemented by the authorities. In addition, COVID-19 may impact market conditions and the Company’s ability to seek additional funding or enter into partnerships. Particularly, delays in the supply of drug substance or drug products, in the initiation or the timing of results of preclinical and/or clinical trials, as well as delays linked to the responsiveness of regulatory authorities could occur, which could potentially have an impact on the Company’s development programs and partnered programs. The Company will continue to actively monitor the situation.

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about POXEL
10/21Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Qu..
AQ
10/20POXEL : Corporate Presentation - English
PU
10/20POXEL : Provides Corporate Update and Reports Cash and Revenue for the Third Qua..
BU
10/16Poxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the Frenc..
AQ
10/15POXEL : Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the French..
BU
10/11POXEL : Corporate Presentation - English
PU
10/07POXEL : Corporate Presentation - English
PU
10/02POXEL : Announces Positive Results from Phase 2a NASH Trial with PXL770, an Oral..
AQ
10/01POXEL : Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral..
BU
09/25Poxel Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-..
AQ
More news
Financials
Sales 2020 14,7 M 17,4 M 17,4 M
Net income 2020 -28,0 M -33,1 M -33,1 M
Net cash 2020 21,6 M 25,5 M 25,5 M
P/E ratio 2020 -5,90x
Yield 2020 -
Capitalization 175 M 207 M 207 M
EV / Sales 2020 10,4x
EV / Sales 2021 2,55x
Nbr of Employees 51
Free-Float 75,3%
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 18,55 €
Last Close Price 6,15 €
Spread / Highest target 241%
Spread / Average Target 202%
Spread / Lowest Target 168%
EPS Revisions
Managers
NameTitle
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Sebastien Bolze Chief Operating Officer & Executive Vice President
Anne Renevot Chief Financial Officer & Executive Vice President
Sophie Hallakou-Bozec Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
POXEL-49.59%207
GILEAD SCIENCES, INC.-7.73%75 173
REGENERON PHARMACEUTICALS56.00%61 638
VERTEX PHARMACEUTICALS-5.39%53 956
WUXI APPTEC CO., LTD.59.09%37 810
BEIGENE, LTD.81.76%27 304